全文获取类型
收费全文 | 106篇 |
免费 | 14篇 |
出版年
2021年 | 1篇 |
2020年 | 3篇 |
2019年 | 1篇 |
2017年 | 2篇 |
2016年 | 1篇 |
2015年 | 4篇 |
2014年 | 3篇 |
2013年 | 1篇 |
2012年 | 2篇 |
2011年 | 2篇 |
2010年 | 5篇 |
2009年 | 7篇 |
2008年 | 6篇 |
2007年 | 11篇 |
2006年 | 5篇 |
2005年 | 8篇 |
2004年 | 6篇 |
2003年 | 9篇 |
2002年 | 4篇 |
2001年 | 14篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1998年 | 3篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1994年 | 1篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1972年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有120条查询结果,搜索用时 359 毫秒
1.
Human interleukin 1 beta is not secreted from hamster fibroblasts when expressed constitutively from a transfected cDNA 总被引:8,自引:2,他引:6 下载免费PDF全文
To understand the secretion and processing of interleukin-1 (IL-1), a Chinese hamster fibroblast cell line (R1610) was transfected with a human IL-1 beta cDNA under the control of the SV40 early promoter and linked to the gene for neomycin resistance. After selecting for transfected cells resistant to G418, two clones were found to constitutively express the IL-1 beta 31-kD precursor which was almost exclusively located in the cytosol. Pulse-chase experiments failed to show any secretion of IL-1 and very little IL-1 activity was detectable in cell supernatants. Furthermore, surface membrane IL-1 activity could not be detected, although low levels of activity could be released upon brief trypsin treatment. Therefore, unlike monocytes, these fibroblast cells lack the mechanism for secreting and processing of IL-1 beta. 相似文献
2.
Processing of precursor interleukin 1 beta and inflammatory disease 总被引:11,自引:0,他引:11
D J Hazuda J Strickler F Kueppers P L Simon P R Young 《The Journal of biological chemistry》1990,265(11):6318-6322
The processing of precursor interleukin 1 beta (IL1 beta) by elastase, cathepsin G, and collagenase, the major proteases released at sites of inflammation, was investigated using recombinant pro-IL1 beta. Each of these proteases cleaved the 31-kDa inactive precursor to a form similar in size and specific activity (greater than 10(8) units/mg) to the 17-kDa mature protein isolated from activated monocytes. Elastase, collagenase, and cathepsin G cleaved the IL1 beta precursor at distinct sites which are amino-terminal to the monocyte-processing site, Ala-117 (Cameron, P., Lumjuco, G., Rodkey, J., Bennett, C., and Schmidt, J. A. (1985) J. Exp. Med. 162, 790-801). Amino-terminal sequencing of the products of digestion by elastase and cathepsin G determined that resultant active IL1 beta proteins contained an additional 13 or 3 amino acids relative to mature IL1 beta. Synovial fluid collected from patients with inflammatory polyarthritis and bronchoalveolar lavage fluid from patients with sarcoidosis supplied similar processing activity(s). Control fluids from patients who had no symptoms of inflammatory disease did not exhibit processing activity. Lavage fluids that processed precursor IL1 beta were demonstrated to contain cathepsin G and/or elastase activity, whereas controls were negative. Because a significant fraction of IL1 beta may be secreted from monocytes as the inactive 31-kDa precursor (Hazuda, D. J., Lee, J. C., and Young, P. R. (1988) J. Biol. Chem. 263, 8473-8479, Bomford, R., Absull, E., Hughes-Jenkins, C., Simpkin, D., and Schmidt, J. (1987) Immunology 62, 543-549, and Mizel, S. B. (1988) in Cellular and Molecular Aspects of Inflammation Poste, G., and Crooke, S., eds) pp. 75-93, Plenum Publishing Corp., New York), these results suggest that in vivo the IL1 beta precursor can be processed after secretion by any of several proteases released at inflammatory sites. 相似文献
3.
Cora E. Lewis John P. Bantle Alain G. Bertoni George Blackburn Frederick L. Brancati George A. Bray Lawrence J. Cheskin Jeffrey M. Curtis Caitlin Egan Mary Evans John P. Foreyt Siran Ghazarian Bethany Barone Gibbs Stephen P. Glasser Edward W. Gregg Helen P. Hazuda Louise Hesson James O. Hill Edward S. Horton Van S. Hubbard John M. Jakicic Robert W. Jeffery Karen C. Johnson Steven E. Kahn Abbas E. Kitabchi Dalane Kitzman William C. Knowler Edward Lipkin Sara Michaels Maria G. Montez David M. Nathan Ebenezer Nyenwe Jennifer Patricio Anne Peters Xavier Pi‐Sunyer Henry Pownall David M. Reboussin Donna H. Ryan Thomas A. Wadden Lynne E. Wagenknecht Holly Wyatt Rena R. Wing Susan Z. Yanovski 《Obesity (Silver Spring, Md.)》2020,28(2):247-258
4.
Ariana M. Chao Thomas A. Wadden Robert I. Berkowitz George Blackburn Paula Bolin Jeanne M. Clark Mace Coday Jeffrey M. Curtis Linda M. Delahanty Gareth R. Dutton Mary Evans Linda J. Ewing John P. Foreyt Linda J. Gay Edward W. Gregg Helen P. Hazuda James O. Hill Edward S. Horton Denise K. Houston John M. Jakicic Robert W. Jeffery Karen C. Johnson Steven E. Kahn William C. Knowler Anne Kure Katherine L. Michalski Maria G. Montez Rebecca H. Neiberg Jennifer Patricio Anne Peters Xavier Pi‐Sunyer Henry Pownall David Reboussin Bruce Redmon W. Jack Rejeski Helmut Steinburg Martha Walker Donald A. Williamson Rena R. Wing Holly Wyatt Susan Z. Yanovski Ping Zhang 《Obesity (Silver Spring, Md.)》2020,28(5):893-901
5.
Nicholas Murgolo Alex G. Therien Bonnie Howell Daniel Klein Kenneth Koeplinger Linda A. Lieberman Gregory C. Adam Jessica Flynn Philip McKenna Gokul Swaminathan Daria J. Hazuda David B. Olsen 《PLoS pathogens》2021,17(2)
Since the initial report of the novel Coronavirus Disease 2019 (COVID-19) emanating from Wuhan, China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally. While the effects of SARS-CoV-2 infection are not completely understood, there appears to be a wide spectrum of disease ranging from mild symptoms to severe respiratory distress, hospitalization, and mortality. There are no Food and Drug Administration (FDA)-approved treatments for COVID-19 aside from remdesivir; early efforts to identify efficacious therapeutics for COVID-19 have mainly focused on drug repurposing screens to identify compounds with antiviral activity against SARS-CoV-2 in cellular infection systems. These screens have yielded intriguing hits, but the use of nonhuman immortalized cell lines derived from non-pulmonary or gastrointestinal origins poses any number of questions in predicting the physiological and pathological relevance of these potential interventions. While our knowledge of this novel virus continues to evolve, our current understanding of the key molecular and cellular interactions involved in SARS-CoV-2 infection is discussed in order to provide a framework for developing the most appropriate in vitro toolbox to support current and future drug discovery efforts. 相似文献
6.
7.
The relationship of social support with treatment adherence and weight loss in Latinos with type 2 diabetes 下载免费PDF全文
8.
Rational design and synthesis of selective BACE-1 inhibitors 总被引:4,自引:0,他引:4
Brady SF Singh S Crouthamel MC Holloway MK Coburn CA Garsky VM Bogusky M Pennington MW Vacca JP Hazuda D Lai MT 《Bioorganic & medicinal chemistry letters》2004,14(3):601-604
An effective approach for enhancing the selectivity of beta-site amyloid precursor protein cleaving enzyme (BACE 1) inhibitors is developed based on the unique features of the S1' pocket of the enzyme. A series of low molecular weight (<600) compounds were synthesized with different moieties at the P1' position. The selectivity of BACE 1 inhibitors versus cathepsin D and renin was enhanced 120-fold by replacing the hydrophobic propyl group with a hydrophilic propionic acid group. 相似文献
9.
Singh SB Zink DL Bills GF Teran A Silverman KC Lingham RB Felock P Hazuda DJ 《Bioorganic & medicinal chemistry letters》2003,13(4):713-717
Integration of viral DNA into host cell DNA is an essential step in retroviral (HIV-1) replication and is catalyzed by HIV-1 integrase. HIV-1 integrase is a novel therapeutic target and is the focus of efforts to identify effective inhibitors that will prevent/or cure HIV infections. Four novel naphtho-gamma-pyrones, belonging to the chaetochromin and ustilaginoidin family, were discovered as inhibitors of HIV-1 integrase from the screening of fungal extracts using a recombinant in vitro assay. These compounds inhibit both the coupled and strand transfer activity of HIV-1 integrase with IC(50) values of 1-3 and 4-12 microM, respectively. The discovery, structure elucidation, chemical modification and the structure-activity relationship of these compounds are described. 相似文献
10.
Singh SB Zink DL Dombrowski AW Polishook JD Ondeyka JG Hirshfield J Felock P Hazuda DJ 《Bioorganic & medicinal chemistry》2003,11(7):1577-1582
HIV-1 integrase is a critical enzyme in the replication of HIV-1. It is absent in the host cells and therefore is a good target for treatment of HIV-1 infections. Integracides are members of the tetracyclic triterpenoids family that were isolated from the fermentation broth of a Fusarium sp. Integracide A, a sulfated ester, exhibited significant inhibitory activity against strand transfer reaction of HIV-1 integrase. The discovery, structure elucidation including single crystal X-ray structure and HIV-1 inhibitory activity of these compounds are described. 相似文献